Harbin Pharmaceutical Group Co., Ltd. (SHA:600664)
China flag China · Delayed Price · Currency is CNY
7.50
+0.08 (1.08%)
Sep 18, 2026, 3:00 PM CST

SHA:600664 Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
512.21361.6628.85395.26465.15371.08
Depreciation & Amortization
260.25263.08288.23304.2310.39307.54
Other Amortization
23.0117.114.6721.8810.9719.61
Loss (Gain) From Sale of Assets
-35.67-3.83-1.03-1.33-161.38-210.74
Asset Writedown & Restructuring Costs
2.892.959.941.1633.592.19
Loss (Gain) From Sale of Investments
-0.32-0.31-12.44-4.48-20.33-0.85
Provision & Write-off of Bad Debts
48.9464.2935.9226.22-1.6710.94
Other Operating Activities
109.18120.8690.07172.59150.13144.79
Change in Accounts Receivable
-223.04224.21118.67-94.42-237.95-613.94
Change in Inventory
-80.67-198.1936.7-119.59277.86-166.46
Change in Accounts Payable
-79.25-410.14-450.37245.21-202.97-30.11
Change in Other Net Operating Assets
-0.04-0.04-0.38---
Operating Cash Flow
534.63439.66792.5949.67622.09-162.44
Operating Cash Flow Growth
-7.45%-44.52%-16.55%52.66%--

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-174.36-150.95-100.81-86.54-89.65-76.7
Sale of Property, Plant & Equipment
65.677.571.235.94151.03177.46
Cash Acquisitions
---0.01---
Divestitures
----156.64--
Other Investing Activities
0.290.290.710.5910.95-9.15
Investing Cash Flow
-108.4-143.09-98.91-206.6472.3491.62

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-1,3471,9053,2072,1581,857
Long-Term Debt Repaid
--1,747-1,958-3,435-2,076-1,220
Lease Payments
-53.71-48.23-48.87-50.76-45.45-46.25
Net Debt Issued (Repaid)
-62.78-400.45-53.49-228.2382.06637.06
Issuance of Common Stock
---3.7316.9815.53
Repurchase of Common Stock
---3.98-8.36--
Common Dividends Paid
-29.32-33.29-47.11-44.16-54.3-61.55
Other Financing Activities
-10.51-23.45-21.02424.97129.88-197.78
Financing Cash Flow
-102.61-457.19-125.61147.94174.62393.26

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-3.78-2.692.240.923.74-2.91
Net Cash Flow
319.84-163.31570.22891.89872.79319.54

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
360.27288.71691.69863.14532.45-239.13
Free Cash Flow Growth
-22.87%-58.26%-19.86%62.11%--
Free Cash Flow Margin
2.23%1.81%4.28%5.58%3.86%-1.87%
Free Cash Flow Per Share
0.140.110.280.350.21-0.10
Levered Free Cash Flow
320.44427.15636.83898.47837.21310.96
Unlevered Free Cash Flow
345.39453.75674.37933.76890.67376.68
Free Cash Flow After Leases
306.55240.48642.81812.38487-285.39

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
757.99732.3810.92815.72728.98711.43
Change in Working Capital
-385.86-386.05-301.734.17-164.76-807.01